EGFR and non-small cell lung carcinoma: Four previously conducted large (>4,000 patients) randomized phase III trials on chemotherapy with or without concomitant administration of an EGFR tyrosine kinase inhibitor in unselected patients with advanced-stage NSCLC, did not demonstrate any correlation between combination treatment and improvement in clinical outcome (11).